Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes

Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have emerged as important therapeutic agents, with benefits extending beyond glycaemic control and weight reduction. This narrative review aimed to examine their pleiotropic effects across multiple organ systems, addressing cardiovascular, renal, cardiac, respiratory, hepatic, neurological and behavioural outcomes, as well as emerging safety concerns. A non-systematic literature review was conducted in PubMed/MEDLINE in November 2026, covering publications from 2018 to 2026. Twelve references were selected and qualitatively synthesized. The findings demonstrated consistent cardiovascular benefits, including reduced major adverse cardiovascular events, alongside improvements in symptoms and functional capacity in heart failure with preserved ejection fraction. Evidence also indicated kidney protection, substantial reductions in obstructive sleep apnoea severity with tirzepatide, and improvements in metabolic dysfunction-associated steatohepatitis. Conversely, potential neuroprotective effects and benefits in addictive behaviours remain preliminary and require confirmation through randomized clinical trials. Safety findings predominantly involved gastrointestinal adverse events, while a modest association with nonarteritic anterior ischaemic optic neuropathy warrants further investigation. High treatment discontinuation rates represent an important challenge to long-term effectiveness. In conclusion, incretin-based therapies demonstrate clinically relevant multisystem benefits, although their mechanisms, long-term safety and weight-independent effects require further investigation.

Authors

Publication Details

Journal
International Health Sciences Review
Published
2026-11-21
DOI
https://doi.org/10.70164/ihsr.v2i6.281
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes

Letícia de Oliveira Rodrigues, Bibiana Born Vinholes, Isabela Krambeck Borges, M. Lobo et al.
International Health Sciences Review
Diabetes Treatment and Management
article

Pleiotropic effects of GLP-1 and GIP receptor agonists: Far beyond obesity and diabetes

Letícia de Oliveira Rodrigues, Bibiana Born Vinholes, Isabela Krambeck Borges, M. Lobo, Valentina Pena Tourinho, Anna Luisa De Lima Pinto, Gabriel Da Cruz D'Angelo, Luiza Parella Zapparoli, Caterina Fonk dos Santos, Maria Eduarda Bellini Moreno, Livia Andreassa Gomes, Maria Clara Ribeiro Mnayarji, Júlia Beatriz Rodrigues Alves, Ana Luíza Gugelmin Zimmermann, Henri Yuli Lourenço Prado de Almeida
article en

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have emerged as important therapeutic agents, with benefits extending beyond glycaemic control and weight reduction. This narrative review aimed to examine their pleiotropic effects across multiple organ systems, addressing cardiovascular, renal, cardiac, respiratory, hepatic, neurological and behavioural outcomes, as well as emerging safety concerns. A non-systematic literature review was conducted in PubMed/MEDLINE in November 2026, covering publications from 2018 to 2026. Twelve references were selected and qualitatively synthesized. The findings demonstrated consistent cardiovascular benefits, including reduced major adverse cardiovascular events, alongside improvements in symptoms and functional capacity in heart failure with preserved ejection fraction. Evidence also indicated kidney protection, substantial reductions in obstructive sleep apnoea severity with tirzepatide, and improvements in metabolic dysfunction-associated steatohepatitis. Conversely, potential neuroprotective effects and benefits in addictive behaviours remain preliminary and require confirmation through randomized clinical trials. Safety findings predominantly involved gastrointestinal adverse events, while a modest association with nonarteritic anterior ischaemic optic neuropathy warrants further investigation. High treatment discontinuation rates represent an important challenge to long-term effectiveness. In conclusion, incretin-based therapies demonstrate clinically relevant multisystem benefits, although their mechanisms, long-term safety and weight-independent effects require further investigation.

International Health Sciences ReviewVol. 2(6)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon